Haemophilia

Article	Citations
AHP Oral Abstracts	66
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial	40
13th BIC International Conference	37
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	35
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable	34
New Treatment in Haemophilia: Challenges, Controversies and Uncertainties	33
The importance and evolution of bleeding disorder registries	31
Into a brave new world: Haemophilia A & von Willebrand Disease Surgery with novel therapies	30
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update	29
The detrimental effects of iron to the joint; aggravation by inflammation	28
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody	28
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?	28
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review	27
Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population	27
CCS_Book of abstracts	27
Competence and Confidence: An Evaluation of Physiotherapists' Knowledge and Self‐Perception About Physical Activity and Exercise in Patients With Haemophilia	27
The legacy of haemophilia: Memories and reflections from three survivors	24
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia	24
Issue Information	23
Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions	22
Initial von Willebrand factor antigen values in adolescent females predict future values	21
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study	21
Wearable activity trackers in young people with haemophilia: What needs to be considered?	21
Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement	20
Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre	20

PUBLICATION ONLY ABSTRACTS	20
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective	19
Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review	19
Cost Analysis of Radioactive Versus Arthroscopic Synovectomy in Haemophilia: A Brazilian Modelling Approach	18
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow‐up from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)	18
Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency	18
	18
The UK Infected Blood Inquiry: A Personal Reflection	18
People With Haemophilia as Data Coordinators: An Analysis of the Ethics and Feasibility of Self‐Management With Personal Health Records	17
Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy	17
Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience	17
Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries	17
Clinical outcomes of low‐dose pharmacokinetic‐guided extended half‐life versus low‐dose standard half‐life factor VIII concentrate prophylaxis in haemophilia A patients	17
Severe Congenital Factor X Deficiency in an Indian Child With a Concomitant Novel ITGA2 Variant	16
The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033	16
Profiling of Anti‐FVIII Antibodies in Acquired Haemophilia A: ‘Insights into Domain Specificity, Isotype Variability, and Clinical Correlations’	16
Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies	16
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	16
Development of the World Federation of Hemophilia Shared Decision‐Making Tool	16
	16
Towards achieving a haemophilia‐free mind	15
Assessment of rare bleeding disorders in adolescents with heavy menstrual bleeding	15
Occurrence of familial Mediterranean fever in haemophilia patients	15
AUTHOR INDEX	15
Tandem and inverted duplications in haemophilia A: Breakpoint characterisation provides insight into possible rearrangement mechanisms	14
Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis	14
Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes	14
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	14
Factor XIII levels correlate with fibrinogen concentrations in patients with venous malformations	14
A 10‐year single‐institution retrospective review of treatment for acquired hemophilia A	14
Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata	14
The lived experience of mothers of children with haemophilia in Jordan: A phenomenological study	14
Factors associated with physical activity in young people with haemophilia A on prophylaxis	14
Emicizumab and asparaginase, A first experience to share	14
Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project	14
Pharmacokinetic profile of children with haemophilia A receiving low‐dose FVIII prophylaxis in Indonesia: A single centre experience	14
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials	14
IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy	14
P2RY12‐Related Platelet Dysfunction in an Indian Child: Unravelling the Diagnostic Enigma of Suspected Platelet Storage Pool Disorder	13
Artificial Intelligence Applications in Haemophilia Care: A Narrative Review of the Literature	13
Clinical Course of Residual Flexion Contracture After Total Knee Arthroplasty in Patients With Haemophilic Arthropathy	13
Development of a target product profile (TPP) for haemophilia point‐of‐care (POC) diagnostic devices for low‐resource countries and remote settings	13
Validating the Online Self‐Administered Bleeding Assessment Tool (Self‐BAT) as a Screening Tool for Bleeding Disorders	13
The Swiss Haemophilia Registry–Report From the First 8 Years	13
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review	13
Ankle joint distraction is a promising alternative treatment for patients with severe haemophilic ankle arthropathy	12
Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi‐country severe WAPPS‐Hemo haemophilia patients	12
Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience	12
von Willebrand disease and von Willebrand factor	12
Safety, pharmacokinetics and efficacy of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A	12

The state of oral health in patients with haemophilia in the Netherlands	12
Adjunctive daratumumab can induce rapid remission in acquired haemophilia A with poor prognostic markers	12
	12
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease	12
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study	12
Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe	11
Management of Persons With Haemophilia Requiring Antithrombotic Therapy: A Canadian Modified Delphi Consensus Study	11
F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A	11
Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study	11
Clotting Factor Concentration During Menstrual Phases in Women With and Without Heavy Menstrual Bleeding: A Systematic Review and Meta‐Analysis	11
Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis	11
	11
Performance on the iSTEP and 10 m‐ISWT in boys with haemophilia	11
Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real‐Life Case Series and Literature Review	11
Correction to “Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Hemophilia A”	11
Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation	11
Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen	11
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity	10
Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy	10
Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study	10
Author Index	10
The haemophilia joint health score for the assessment of joint health in patients with haemophilia	10
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies	10
Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis	10
Retraction	10
Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients	10
Book of Abstracts	10
Assessing the Impact of the 2021 VWD Guidelines on the Diagnosis/Management of Low VWF Patients	10
Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system	10
Validity and reliability test of the Indonesian version of the PedHALshort questionnaire	10
Does the method of telehealth delivery affect the physiotherapy management of adults with bleeding disorders? A comparison of audioconferencing and videoconferencing	9
Democratisation of physiotherapy for people with haemophilia	9
	9
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	9
Comparison of free‐living physical activity measurements between ActiGraph GT3X‐BT and Fitbit Charge 3 in young people with haemophilia	9
COMMITTEE LIST	9
Breaking barriers in haemophilia A care: One‐year real‐world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal	9
Patient‐centred research agenda for females with bleeding disorders	9
Endothelial specific isoform of type XVIII collagen (COL‐18N): A marker of vascular integrity in haemophilic arthropathy	9
The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review	9
Haemophilia Joint Health Score Ranges Across the Lifespan: Variation by Haemophilia Type and Severity	9
Scientific Review of the UK Infected Blood Inquiry Report: A Personal Reflection	9
Gene therapy: Practical aspects of implementation	9
Integrating Next‐Generation Sequencing Into Routine Molecular Diagnosis of Inherited Coagulation Factor Deficiencies: Real‐World Data From Spanish Patients	9
Identifying performance‐based outcome measures of physical function in people with haemophilia (IPOP)	9
Diagnosis and management of factor XI alloinhibitors in patients with congenital factor XI deficiency—A large single‐centre experience	9
European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice	9
HRQoL and psychosocial aspects of burden on caregivers to children with moderate or severe von Willebrand disease	9
Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature	9
Commentary: The Infected Blood Inquiry in the United Kingdom—Let the Dust Settle	9
Dental Neglect by Individuals With Haemophilia: Clinical Challenges and Solutions	9
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab	9
Clotting factor activity levels and bleeding risk in people with haemophilia playing sports	9
Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State	8
Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan	8
Accuracy and clinical role of digital templating for total knee arthroplasty performed on haemophilic knees	8
UKNEQAS Blood Coagulation Factor Nine (FIX) Gene Therapy Supplementary Exercise 2025	8
European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients	8
Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2)	8
	8
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B	8
Comprehensive Analysis of Surgical Interventions for Musculoskeletal Disorders in Patients With Bleeding Disorders: Report From a Subspecialty Unit in a Developing Country	8
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?	8
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B	8
Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience	8
Enhancing Engagement to Support Shared Decision Making Within Haemophilia: Development of Materials for People With Haemophilia, Caregivers and Healthcare Professionals	8
Harmonizing patient‐reported outcome measurements in inherited bleeding disorders with PROMIS	8
Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications	8
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers’ and Healthcare Providers’ Perspectives	8
Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐ce	8
Abstract	8
Bone marrow oedema syndrome as a cause of chronic knee pain in a person with severe Haemophilia A	8
Five new F10 variants in hereditary factor x deficiency detected by high‐throughput sequencing	8
Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments	8
Haemophilia care in Asia: Learning from clinical practice in some Asian countries	8
Deciphering a novel complex inversion affecting F8 in a family with severe haemophilia A by optical genome mapping	7
Haemophilic Elbow Arthropathy: Mechanisms, Management and Future Perspectives	7
Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study	7
Issue Information	7
Acquired haemophilia A: A 15‐year population‐based review of incidence rate, patient demographics and treatment outcomes	7

Efficacy and Safety of Aspiration and Intra‐Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study	7
Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia	7
	7
Diagnosis of rare bleeding disorders	7
Bridging the gap: Survey highlights challenges and solutions in outreach and identification of people with inherited bleeding disorders	7
Psychophysical assessment of pain in adults with moderate and severe haemophilia: A cross‐sectional study	7
Central Nervous System Bleeding in Children With Haemophilia in Limited Resource	7
Morphological Variations in Haemophilic Knee Arthropathy: Surgical Implications for Total Knee Arthroplasty Component Selection and Bone Preparation	7
Hemizygous FGG p.Ala108Gly in a hypofibrinogenemic patient with a heterozygous 14.8 Mb deletion encompassing the entire fibrinogen gene cluster	7
Committee List	7
Pain while injecting emicizumab predominant in children, a report of Dutch patient experiences	7
Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study	7
Radiological Stage of Hemophilic Arthropathy of Knee Does Not Correlate With Clinical Variables	7
Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B	6
	6
Abstract	6
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD	6
POSTER ABSTRACTS	6
Defining success in haemophilia care – Are we doing it right?	6
Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia	6
Issue Information	6
Coagulation Factor Consumption and Medium‐ to Long‐Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia	6
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot®) and emicizumab in patients with haemophilia A and inhibitors and	6
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy	6
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	6
Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center	6
A Psychometric Analysis of the Haemophilia Quality of Life Questionnaire for Adults Physical Health Subscale and Total Scores: Data From the Phase 3 XTEND‐1 Trial in Patients With Severe Haemophilia A	6
	6
Prevalence and Impact of Heavy Menstrual Bleeding in Women With von Willebrand Disease Across Age Groups: A Retrospective Study	6
Identification and Analysis of Mitochondria‐Related Proteins in Haemophilic Arthritis Synovial Membranes Based on Proteomic Analysis	6
Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab	6
Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience	6
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China	6
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	6
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy	6
Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause	6
Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database	6
Methylome analysis for haemophilia A intron 22 inversion patients with and without inhibitors: A pilot study	6
Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry	6
The effect of a virtual child disease management programme on burden and social adjustment of caregivers of children with coagulation factor deficiencies	6
Invited Medical Presentation Abstracts	6
Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group	6
UK haemophilia consultant access to foot and ankle services and concurrent patient impact questionnaire responses to foot and ankle interventions	6
Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series	6
Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding	6
Diagnosis and treatment of von Willebrand disease in 2024 and beyond	6
A national assessment of standards of care for inherited bleeding disorders in Canada	6
Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 1	5
Association of factor expression levels with annual bleeding rate in people with haemophilia B	5
Differences and similarities in patient‐reported outcomes among men and women with haemophilia	5
	5
Germline variants of the immune checkpoint proteins PD‐1, PD‐l1 and CTLA‐4 and immune tolerance induction outcome in patients with inherited haemophilia A	5
Evaluation of Access to Care for Women Carriers of Haemophilia in Haemophilia Treatment Centres: A Multinational Experience	5
Desmopressin Response in Children With Platelet Disorders May Depend on the Presence of a Genetic Cause When Response Is Measured With Von Willebrand Activity and Platelet Function Analyser	5
Cross‐Sectional Survey of Haemophilia Treatment Centres (HTCs) in India: Towards a Context‑Sensitive Stratification Model	5
Haemostatic Prophylaxis and Colonoscopy Outcomes in Patients With Bleeding Disorders: An Update	5
Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment	5
Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe	5
Real‐world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea	5
Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States	5
HEAD‐US Score and Cartilage Biomarkers in Patients With Severe Haemophilia A Who Receive Low‐Dose Factor VIII Prophylaxis	5
Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B	5
Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group	5
EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B	5
Acquired bleeding disorders	5
Depression and anxiety in persons with Von Willebrand disease	5
Women and girls’ participation in haemophilia clinical trials	5
Molecular spectrum of inherited FVII deficiency in North India revealed a recurrent variant with a founder effect	5
Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices	5
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A	5
The Humanitarian and Medical Crisis in Palestinian Territories: The Plight of Patients With Congenital Bleeding Disorders and Health Care Under Siege	5
Issue Information	5
AUTHOR INDEX	5
ImpaHCta—Haemophilia Carriers Quality of Life Assessment	5
Supporting Patient‐Centred Decisions on Gene Therapy for Haemophilia A: A Conceptual Model	5
Successful Orthopaedic Surgeries With World Federation of Haemophilia Humanitarian Aid Program in Resource‐Limited Settings	4
	4
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐se	4
Specialist training in thrombosis and haemostasis across Europe: From aspirations to actions	4
Preference of treatment characteristics among people with haemophilia or their caregivers, and physicians in the Japanese healthcare environment	4
Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays	4
No difference in quality of life between persons with severe haemophilia A and B	4
Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China	4
Issue Information	4
	4
Utilising Thrombin Generation Assay to Guide Co‐Administration of Factor Therapies With Fitusiran	4
Longitudinal observations of TFPI levels in paediatric Haemophilia A patients	4
The impact of emicizumab on the clinical validation of new therapies for haemophilia A	4
Neuroinflammatory markers in patients with haemophilia and healthy controls: Where are the differences?	4
Issue Information	4
Retraction Statement: Poster Abstracts	4
Review of interventions and effectiveness for heavy menstrual bleeding in women with moderate and severe von Willebrand disease	4
Iron overload causes macrophages to produce a pro‐inflammatory phenotype in the synovium of hemophiliac arthritis via the acetyl‐p53 pathway	4
Is Incubation for 30 Minutes at 56°C Sufficient to Fully Inactivate Efanesoctocog Alfa?	4
Issue Information	4